Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

BioLife Solutions Inc (BLFS) reports a 29% annual revenue increase and outlines strategic initiatives for continued growth in 2026.

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ago.

Q4 2025 earnings call recap: 2026 revenue guidance, margin outlook, CGT demand drivers, and QKine partnership.

BOTHELL, Wash., March 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, today announced three new patents for bioproduction tools related to ...

BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment ...

BioLife Solutions, a leading provider of bioproduction tools and services, is poised for growth as the demand for biologics and regenerative medicine increases. CryoStor and HypoThermosol have shown significant improvement to the post-preservation ...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems the smart money knows that debt - which is usually ...